Login
$IMVT
$33.28 -$0.90 (2.63%) Live

$IMVT 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

DURHAM, N.C. November 9, 2026 – Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its second ...

03 Sep 2026 8-K: Submission of Matters to a Vote of Security Holders

On September 2, 2026, Immunovant, Inc. (“Immunovant”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). There were 198,373,370 shares of common stock and Series A preferred stock represented at the Annual Meeting by va...

06 Aug 2026 8-K: Results of Operations and Financial Condition

DURHAM, N.C. August 6, 2026 – Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its first fis...

20 May 2026 8-K: Results of Operations and Financial Condition

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

06 Feb 2026 8-K: Results of Operations and Financial Condition

DURHAM, N.C. February 6, 2026 – Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended Decem...

12 Dec 2025 8-K: Other Events

Immunovant, Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC the “Underwriter,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), with r...

11 Dec 2025 8-K: Other Events

On December 10, 2025, Immunovant, Inc. (the “Company”) announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to the Company of approximately $550 million, before deducting underwriting dis...

21 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

Michael Geffner, M.D., M.B.A., ceased serving as the Chief Medical Officer of Immunovant, Inc. (the “Company”), effective November 21, 2025 (“Separation Date”), in connection with the Company’s restructuring of its R&D leadership structu...

10 Nov 2025 8-K: Results of Operations and Financial Condition

NEW YORK, November 10, 2025 – Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the second quarter ended Septem...

03 Sep 2025 8-K: Regulation FD Disclosure; Other Events

Targeted science, Tailored solutions for people with autoimmune disease Batoclimab Graves’ Disease Proof-of-Concept Study Remission Data September 2025 Exhibit 99.2

28 Aug 2025 8-K: Submission of Matters to a Vote of Security Holders

On August 27, 2025, Immunovant, Inc. (“Immunovant”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). There were 165,885,480 shares of common stock and Series A preferred stock represented at the Annual Meeting by vali...

11 Aug 2025 8-K: Results of Operations and Financial Condition

NEW YORK, August 11, 2025 – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for the quart...

29 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

As previously disclosed, on April 18, 2025, the Board of Directors (the “Board”) of Immunovant, Inc. (the “Company”) appointed Eric Venker, M.D., Pharm.D., as Chief Executive Officer and principal executive officer of the Company, effect...

29 May 2025 8-K: Results of Operations and Financial Condition

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

21 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more

2 Forward-Looking Statements Roivant Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those...

19 Mar 2025 8-K: Regulation FD Disclosure; Other Events

Targeted science, Tailored solutions for people with autoimmune disease MG & CIDP Results March 2025 Exhibit 99.2

06 Feb 2025 8-K: Results of Operations and Financial Condition

NEW YORK, Feb. 6, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal third...

24 Jan 2025 8-K: Other Events

We have acted as counsel to Immunovant, Inc., a Delaware corporation (the “Company”), in connection with the filing by the Company of a prospectus supplement dated January 24, 2025 (the “Prospectus Supplement”) with the Securities and Ex...

14 Jan 2025 8-K: Regulation FD Disclosure

Targeted science, Tailored solutions for people with autoimmune disease 2025 J.P. Morgan Healthcare Conference January 14, 2025 Exhibit 99.1

13 Jan 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support